Wanlim Kim, mD; ilKyu Han, mD, PHD; HWan Jun Jae, mD, PHD; SeungcHeol Kang, mD; Sang a. lee, BS; Jong SeoP Kim, mD, PHD; Han-Soo Kim, mD, PHD Preoperative transcatheter arterial embolization for hypervascular bone tumors is now widely accepted as a safe and effective procedure for reducing intraoperative blood loss and surgical morbidity. However, few studies have reported the use of preoperative transcatheter arterial embolization for nonspine bone metastases from hepatocellular carcinoma. The goal of this study was to assess the effect of preoperative embolization on blood loss and clinical outcomes in surgery for nonspine bone metastasis from hepatocellular carcinoma. Seventy-five patients with metastases from hepatocellular carcinoma to the pelvis and extremities were reviewed retrospectively. The study population consisted of 62 men and 13 women, with a mean age of 64.6 years (range, 40.0-80.1). The average follow-up period was 8.2 months (range, 0.3-66.1). Twenty-two patients underwent transcatheter arterial embolization for preoperative devascularization (group A), and 53 patients underwent operative treatment only (group B). The proportion of pelvis metastases was significantly higher (P<.001) and operative time was longer (P=.006) in group A than in group B. However, a significantly smaller decrease in hemoglobin level before and after surgery was seen in group A (P=.017). No significant differences were seen in intraoperative estimated blood loss, perioperative hemoglobin level, number of allogeneic transfusions, or length of hospitalization between the 2 groups. Preoperative transcatheter arterial embolization is an effective means to reduce bleeding during surgery for nonspine metastases from hepatocellular carcinoma. In general, surgical procedures that included transcatheter arterial embolization took longer and were more extensive. [Orthopedics. 2015; 38(2):e99-e105.] The authors are
Preoperative transcatheter arterial embolization for hypervascular bone tumors is now widely accepted as a safe and effective procedure for reducing intraoperative blood loss and surgical morbidity. However, few studies have reported the use of preoperative transcatheter arterial embolization for nonspine bone metastases from hepatocellular carcinoma. The goal of this study was to assess the effect of preoperative embolization on blood loss and clinical outcomes in surgery for nonspine bone metastasis from hepatocellular carcinoma. Seventy-five patients with metastases from hepatocellular carcinoma to the pelvis and extremities were reviewed retrospectively. The study population consisted of 62 men and 13 women, with a mean age of 64.6 years (range, 40.0-80.1). The average follow-up period was 8.2 months (range, 0.3-66.1). Twenty-two patients underwent transcatheter arterial embolization for preoperative devascularization (group A), and 53 patients underwent operative treatment only (group B). The proportion of pelvis metastases was significantly higher (P<.001) and operative time was longer (P=.006) in group A than in group B. However, a significantly smaller decrease in hemoglobin level before and after surgery was seen in group A (P=.017). No significant differences were seen in intraoperative estimated blood loss, perioperative hemoglobin level, number of allogeneic transfusions, or length of hospitalization between the 2 groups. Preoperative transcatheter arterial embolization is an effective means to reduce bleeding during surgery for nonspine metastases from hepatocellular carcinoma. In general, surgical procedures that included transcatheter arterial embolization took longer and were more extensive. [Orthopedics. 2015; 38(2):e99-e105.] H epatocellular carcinoma is the most common primary malignancy of the liver, with a worldwide incidence of approximately 600,000 new cases per year; this incidence varies substantially among geographic locations. 1, 2 Asian countries account for nearly 78% of the annual incidence. The major etiology is chronic hepatitis B virus infection in Northeast and Southeast Asia. Mortality rates for hepatocellular carcinoma are increasing in Asian countries, and this trend is expected to continue for 3 to 4 decades. 2 Hepatocellular carcinoma is a wellknown hypervascular tumor that is likely to metastasize to the bone in 3% to 20% of cases. [3] [4] [5] [6] Because chronic viral hepatitis and liver cirrhosis are leading causes of hepatocellular carcinoma, patients with hepatocellular carcinoma may have a tendency to bleed. Most bone metastases from hepatocellular carcinoma present as osteolytic lesions on plain radiography. Presenting symptoms vary from mild bone pain to pathologic fracture, depending on the degree of bone involvement. Once skeletal metastases occur, the morbidity rate increases and quality of life significantly decreases. For these reasons, many orthopedic surgeons recently began to treat bone metastases aggressively to improve patient quality of life and life expectancy in select cases. [7] [8] [9] Several reports described preoperative transcatheter arterial embolization as a treatment for bone metastases from hypervascular tumors such as renal cell carcinoma and thyroid carcinoma. 5, [10] [11] [12] [13] [14] [15] In renal cell carcinoma, preoperative transcatheter arterial embolization has been shown to help in obtaining adequate surgical margins and durable skeletal reconstruction and lowering patient morbidity because it decreases intraoperative blood loss. [12] [13] [14] [15] Because of the high incidence of hepatocellular carcinoma in Asian countries, the prolonged patient survival time, and the consequent increase in the detection of metastases, appropriate treatment strategies are relevant. However, to the authors' knowledge, few studies have reported preoperative transcatheter arterial embolization for the treatment of bone metastases from hepatocellular carcinoma, especially focusing on reducing blood loss and the need for transfusion during surgery and in the early postoperative period.
The goal of this study was to evaluate the effect of preoperative transcatheter arterial embolization on blood loss and clinical outcomes in surgery for bone metastases of the pelvis and extremities from hepatocellular carcinoma. The authors analyzed various patient and perioperative parameters that may have been related to bleeding issues.
Materials and Methods
The authors retrospectively reviewed the medical records of 285 patients with hepatocellular carcinoma who underwent surgery for bone metastases between 1997 and 2012 at the authors' institution. To construct a more homogeneous group, the following exclusion criteria were applied: (1) bone metastases at sites other than the pelvis and extremities (n=168); (2) revision surgery (n=35); and (3) less than 70% obliteration of tumor staining (n=7). The remaining 75 patients were included in the study. Institutional review board approval was obtained for retrospective review of medical records.
The study population included 62 men and 13 women, with a mean age of 60.6 years (range, 40.0-80.1 years). Average follow-up time was 8.2 months (range, 0.3-66.1). Location of the primary tumor included the femur (n=36), humerus (n=22), pelvis (n=9), pelvis and proximal femur (n=3), and other sites (n=5).
The following data were collected from medical records: (1) demographic and preoperative variables, including age, sex, preceding cause of hepatocellular carcinoma, modified Child-Pugh class, preoperative hemoglobin level, platelet count, prothrombin time, activated partial thromboplastin time, presence of pathologic fracture, and location of bone metastases; (2) intraoperative and early postoperative variables, including extent of surgery, operative time, estimated blood loss, number of transfusions during surgery, hemoglobin level on postoperative days 0 and 2, decrease in hemoglobin level on postoperative days 0 and 2, and complications of preoperative transcatheter arterial embolization; and (3) postoperative outcome variables, including length of hospitalization and 1-month postoperative mortality rate during the study period.
Surgery was performed for pathologic fractures in 47 cases and for impending fractures in 28 cases. The surgical indication in the authors' series was based on the following: modified Child-Pugh class A or B, remaining life expectancy of more than the recovery period after surgery, and expected improvement in quality of life. Surgical treatment included curettage, polymethylmethacrylate insertion, and internal fixation in 49 patients; en bloc excision of a metastatic lesion and tumor prosthetic reconstruction in 19 patients; en bloc excision without reconstruction in 4 patients; and curettage and polymethylmethacrylate insertion in 3 patients.
Preoperative transcatheter arterial embolization was performed by experienced interventional radiologists at the authors' institution with the goal of devascularization. Preoperative transcatheter arterial embolization was performed in cases of intralesional surgery involving the pelvis or a large bone segment of the extremities or en bloc surgery in patients with coagulation abnormalities. Because the authors did not perform aggressive preoperative transcatheter arterial embolization to devascularize the metastatic lesion in the early period of their study, those early patients did not undergo preoperative transcatheter arterial embolization even if they had the indications noted earlier. Various approaches were used, depending on the anatomic location of the metastatic lesion. On arteriography, embolization was performed after superselection of the feeding artery to the tumor and identification of hypervascular tumor staining. The embolization material used was Gelfoam (Pfizer, New York, New York), polyvinyl alcohol, or both, depending on the size and location of feeding arteries to the metastatic tumor. The success of embolization was evaluated by comparing pre-and postembolization arteriograms (Figure) . On average, surgery was performed 1.7 days (range, 0-4) after transcatheter arterial embolization, with 91% of patients undergoing surgery within 3 days. There was 1 complication related to preoperative transcatheter arterial embolization, for a complication rate of 4.5%. In that patient, a branch of the feeding vessel ruptured during superselection of the feeder artery; therefore, the interventional radiologist embolized the ruptured vessel with a glue-ethiodized oil mixture. Another patient had postembolization fever, possibly as a result of postembolization syndrome, that subsided 3 days after transcatheter arterial embolization. 
results
Preoperative transcatheter arterial embolization was performed in 22 patients (group A), and 53 patients underwent operative treatment without preoperative transcatheter arterial embolization (group B). Preoperative variables were not significantly different between the 2 groups except for the occurrence of pelvis metastasis (Table 1) , which was significantly higher in group A (P<.001). In both groups, in patients with hepatocellular cancer, the most common underlying medical condition was hepatitis B virus-related liver cirrhosis. This likely reflects the high prevalence of hepatitis B virus infection in Asia compared with the Americas or Europe, where hepatitis C virus-related liver cirrhosis is the leading cause of hepatocellular carcinoma. No patients in either group had modified Child-Pugh class C function, which is considered a contraindication to surgery. Preoperative parameters related to hemorrhagic tendencies, such as thrombocytopenia, prothrombin time prolongation, and activated partial thromboplastin time, were not significantly different between the 2 groups. Abnormal values included only mild nonsignificant deviations from reference values that were not sufficient to prevent operative treatment. All metastatic lesions appeared osteolytic, and 57.3% of patients had a pathologic fracture.
Operative time was significantly longer (P=.006) in group A than in group B ( Table 2) . Extent of surgery, estimated blood loss during the index operation, number of allogeneic transfusions, and hemoglobin level did not differ significantly between groups. However, the decreases in hemoglobin level from the preoperative value to the values on postoperative days 0 and 2 were significantly smaller in group A than in group B.
The authors stratified the study population according to the presence of pelvis metastasis and analyzed the variables shown in Table 2 . In patients with pelvis metastasis, the decrease in hemoglobin level from preoperative values to postoperative day 2 values was significantly smaller in the group with preoperative transcatheter arterial embolization (P=.002), whereas other variables were not significantly different between groups. In patients without pelvis metastasis, mean operative time was longer (P=.021) and the decrease in hemoglobin levels from preoperative values to postoperative day 1 values was significantly smaller (P=.036) in the group with preoperative transcatheter arterial embolization. The decrease in hemoglobin levels from preoperative values to postoperative day 2 values was smaller in the group with transcatheter arterial embolization, but the differences were not statistically significant (P=.068).
Estimated mean survival time was 13.1 months in group A and 19.3 months in group B; however, the difference was not significant (P=.239). Mean length of hospitalization was 27.7 days (range, 7-194 days), and 3 patients (4%) died of liver surgery within 1 month after surgery. The postoperative outcome variables mortality rate and mean length of hospitalization were not significantly different between the 2 groups. In patients with en bloc excision for bone metastasis, survival rate was better than in the group with intralesional or marginal excision; however, this difference was not significant (P=.077). The survival of patients with hepatocellular carcinoma is increasing because of advances in the diagnosis and treatment of the primary lesion. Consequently, more patients are diagnosed with bone metastasis. 1 Bone metastasis is a major extrahepatic disease associated with hepatocellular carcinoma and usually presents symptomatically with bone pain, neurologic symptoms, and/or pathologic fracture, impairing daily activity and decreasing quality of life. 6 Although bone metastasis does not jeopardize short-term survival in patients with hepatocellular carcinoma, the symptoms can present major challenges for orthopedic surgeons in choosing the appropriate treatment. Therefore, new long-term therapies are needed. 6 Bone metastasis from hepatocellular carcinoma has the following characteristics: (1) the lesions present as hypervascular metastases 3, 4, 6, 16, 17 ; (2) patients may have a bleeding diathesis, ranging from normal to severe bleeding; and (3) the degree of coagulopathy varies according to patient liver function. 18 Impairment of liver function is an important factor in surgical planning. Surgery for bone metastases is not feasible in patients with modified Child-Pugh class C function because of the high risk of intraoperative and postoperative bleeding. [19] [20] [21] [22] Surgery is indicated for impending fracture, pathologic fracture, or spinal cord compression, as well as after the failure of radiation therapy.
14 Because surgical treatment of bone metastasis from hepatocellular carcinoma is often associated with massive bleeding, 16 efforts are made to reduce operative blood loss. However, blood salvage techniques are contraindicated because of the risk of further dissemination of tumor cells. 23 Hence, at their institution, the authors perform preoperative transcatheter arterial embolization for bone metastasis from hepatocellular carcinoma if an extensive surgical procedure, with high estimated blood loss, is planned.
Preoperative transcatheter arterial embolization for hypervascular bone tumors is widely accepted as a safe and effective procedure for reducing intraoperative blood loss and surgical morbidity. 14, 24 In several reports, embolization for bone metastasis was also an effective method for palliative treatment of intractable bone pain from metastasis without evidence of delayed bone healing. 14 Compared with the numerous reports on preoperative transcatheter arterial embolization of hypervascular spinal tumors and metastasis from renal cell carcinoma, few studies have reported embolization for preoperative devascularization of long bone metastasis from hepatocellular carcinoma.
In general, preoperative transcatheter arterial embolization is performed no earlier than 3 days before surgery because flow reconstitution through collaterals increases with time. 9, 25 However, some authors showed that a delay to surgery of up to 3 weeks did not affect the results of devascularization. 15 Chatziioannou et al 13 advocated that the authors should attempt total devascularization of the tumor because incomplete devascularization may lead to more blood loss and transfusion than complete devascularization. The criteria used for successful embolization varied in pre- vious studies. 5, 9, 13 The authors excluded patients with less than 70% obliteration of tumor staining. From the perspective of the surgeon, surgery should be performed after complete obliteration of tumor staining. However, it is not always possible to achieve complete embolization because of failed superselective catheterization of the small feeding vessels and the risk of nontarget ischemia. 9 Thus, to achieve better results from transcatheter arterial embolization, orthopedic surgeons and interventional radiologists should cooperate closely. 13 Complications of preoperative transcatheter arterial embolization are rare. 24 When they occur, they are related to the embolized vessel and the materials used. 16 Preoperative transcatheter arterial embolization can potentially induce ischemic changes in the tissue adjacent to the tumor and theoretically may interfere with osseous union. However, there was no evidence of delayed postoperative bone healing or nonunion in a previously reported series.
14 Postembolization syndrome, with symptoms such as fever, pain, and malaise, is common as a side effect, but generally resolves completely within 5 days of symptomatic therapy. 25 Therefore, postembolization syndrome is not usually considered a complication of transcatheter arterial embolization, although it may delay surgery for 2 to 3 days. 14 In the current series, patient characteristics were not significantly different between the patient groups. Some patients had abnormal findings on preoperative coagulation test and platelet count, but the values were not significantly different from normal. The higher proportion of pelvis metastasis and the longer operative time in group A implied that surgical procedures in this group were more extensive and were likely to involve significantly more blood loss. However, estimated blood loss and the need for transfusion were not significantly different between groups; furthermore, the decrease in hemoglobin level was significantly smaller in group A than in group B. When the authors stratified patients according to pelvis metastasis and analyzed the effect of preoperative transcatheter arterial embolization, the results supported the efficacy of transcatheter arterial embolization for bleeding issues. These results indicate that this technique offers an advantage in reducing intraoperative bleeding for selected patients during surgery and in the early postoperative period. Furthermore, although the number of allogeneic transfusions was not significantly different between patients who underwent transcatheter arterial embolization and those who did not, taking into account that surgical procedures that included transcatheter arterial embolization usually took much longer and were more extensive than those without this procedure, the results suggest that this technique may be helpful in reducing the need for allogeneic transfusion. However, these results must be confirmed in future studies with large populations.
This retrospective study involved a review of medical records with a relatively small number of patients who underwent preoperative transcatheter arterial embolization. A prospective randomized study in a large population would be beneficial to determine the effectiveness of embolization compared with surgical treatment without preoperative transcatheter arterial embolization. Second, the size and location of the metastatic lesion and the type of surgery performed were not homogenous and therefore could not be compared directly between groups.
conclusion
To the best of the authors' knowledge, this is the first study of preoperative transcatheter arterial embolization for nonspine metastases from hepatocellular carcinoma. The authors believe that this is relevant information for the treatment of bone metastasis from hepatocellular carcinoma, considering its prevalence, especially in Asian countries. In conclusion, preoperative transcatheter arterial embolization is an effective measure to reduce blood loss without significant complications during surgery for metastases of the extremities from hepatocellular carcinoma.
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